Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 15/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30243962 | 1.00 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL30244308 | 1.00 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL30770628 | 1.00 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL22013513 | 0.92 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL30770356 | 0.92 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL30243890 | 0.92 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL25034025 | 0.83 | PRMT5 (0.35) | NLRP3ATMSMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL22012981 | 0.82 | NLRP3 (0.39) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL20692173 | 0.82 | NLRP3 (0.45) | NLRP3 | |
| SCHEMBL30243871 | 0.82 | NLRP3 (0.45) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885ATM 3588/4885SMN1; SMN2 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.